MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from
convertible debt
$350,000
Proceeds from short-term
loan, related party
$17,000
Net cash provided by
financing activities
$317,000
Canceled cashflow
$50,000
Net decrease in
cash, cash...
-$25,243
Canceled cashflow
$317,000
Stock compensation
expense
$1,641,847
Amortization of debt discount
and deferred...
$145,583
Common shares issued to
investors
$130,766
Change in fair value of
derivative
-$90,080
Accounts receivables
-$49,266
Prepaid expenses and
other current assets
-$5,340
Accounts payable to
related party
$514
Repayment of short-term
loans, others
$50,000
Net cash used in
operating activities
-$342,243
Canceled cashflow
$2,063,396
Net loss before
non-controlling interests
-$2,239,276
Accounts payable and
accrued expenses
-$166,363
Back
Back
Cash Flow
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)
source: myfinsight.com